<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904225</url>
  </required_header>
  <id_info>
    <org_study_id>NPC 2018 Tegio</org_study_id>
    <nct_id>NCT03904225</nct_id>
  </id_info>
  <brief_title>Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis</brief_title>
  <official_title>Efficacy and Safety Evaluation of Tegio Consolidation Therapy in the Treatment of Nasopharyngeal Carcinoma With High Risk of Metastasis: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      oral administration of Tegio capsules for 12 months for NPC patients with high risk of&#xD;
      metastasis (AJCC stage T3-4N2M0 or T1-4N3M0) was tested trying to reduce distant&#xD;
      metastasis，safety was also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, NPC patients (stage T3-4N2M0 or T1-4N3M0) who finished the curative&#xD;
      chemoradiation will be randomized to the observation group and treatment group (60 mg bid,&#xD;
      p.o.，d1-28，q6wks; continued until disease progression, unacceptable toxicity, or over 1&#xD;
      year). The primary endpoint is distant failure-free survival (D-FFS), Secondary end points&#xD;
      include overall survival (OS), locoregional failure-free survival (LR-FFS), progression-free&#xD;
      survival (PFS) and toxic effects,. All efficacy analyses are conducted in the&#xD;
      intention-to-treat population, and the safety population include only patients who receive&#xD;
      their randomly assigned treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>distant metastsis-free survival (DMFS)</measure>
    <time_frame>From date of randomization until the date of first documented distant disease failure, assessed up to 36 months</time_frame>
    <description>distant metastsis-free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>tegio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegio 60mg bid d1-28 q6wks was administered until disease progression, unacceptable toxicity,or over 12monthes within 3monthes after curative chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients was oberved</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur-Gimeracil-Oteracil</intervention_name>
    <description>oral administration for 12 months</description>
    <arm_group_label>tegio</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 ys&#xD;
&#xD;
          2. Performance status of Eastern Cooperative Oncology Group (ECOG) grade 0 -2&#xD;
&#xD;
          3. Tumor staged as 8th American Joint Committee on Cance (AJCC) T3-4N2M0 or T1-4N3M0 with&#xD;
             histologically confirmed&#xD;
&#xD;
          4. Within 12weeks after completion of the curative radiotherapy treatment&#xD;
&#xD;
          5. disease was controlled after radiotherapy&#xD;
&#xD;
          6. with adequate hematologic (neutrophil count &gt; 1.5×10^9/L, hemoglobin &gt; 90g/L and&#xD;
             platelet count &gt; 100×10^9/L), hepatic (alanine aminotransferase, aspartate&#xD;
             aminotransferase ≤ 1.5×ULN, bilirubin ≤ 1.5×ULN, alkaline phosphatase &lt; 2.5×ULN) and&#xD;
             renal function (creatinine clearance &gt; 50 ml/min)&#xD;
&#xD;
          7. Patients must be informed and written informed consent was finished.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. allergic to Tegio.&#xD;
&#xD;
          2. Illness may interfere with oral medication, including dysphagia, chronic diarrhea, or&#xD;
             ileus&#xD;
&#xD;
          3. Prior malignancy except treated basal cell or in situ cervical cancer.&#xD;
&#xD;
          4. Pregnancy or lactation (consider pregnancy test in women of child-bearing age and&#xD;
             emphasize effective contraception during the treatment period).&#xD;
&#xD;
          5. severe comorbidities may bring unacceptable risk or affect the compliance of the&#xD;
             trial, including but not limited to unstable cardiac disease requiring treatment,&#xD;
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose &gt;&#xD;
             1.5×ULN), and emotional disturbance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>feng Jiang, MD</last_name>
    <phone>0086-571-88128202</phone>
    <email>jiangfeng@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen, MD</last_name>
      <phone>86-571-88122098</phone>
      <email>cxzfyun@sina.com</email>
    </contact>
    <investigator>
      <last_name>Xiaozhong Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>Tegio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

